Samsung Electronics Co. and Samsung C&T Corp. are investing $110 million in Grail Inc., betting on the unprofitable biotech’s blood test that promises early detection of dozens of cancers.
The deal, disclosed Friday, grants Samsung C&T exclusive distribution rights for Grail’s Galleri test in South Korea, with potential expansion into Japan and Singapore. Samsung Electronics plans to integrate Grail’s genomic diagnostic technology into its Samsung Health platform.
Grail remains deeply unprofitable, posting a $114 million net loss last quarter and expecting to burn through $310 million in cash this year. The investment, priced at $70.05 per share, is expected to close in early 2026 following regulatory approvals.
The Galleri test, which screens for more than 50 types of cancer from a single blood sample, costs patients up to $950 out of pocket and lacks FDA approval. The company plans to submit for FDA approval in the first half of 2026, though approval wouldn’t be expected until 2027.
Grail has sold 370,000 tests since launching in 2021, generating $34.2 million in revenue during the second quarter. Grail’s stock surged following the announcement, while Samsung C&T shares fell 3%.
